JP2021513541A5 - - Google Patents
Info
- Publication number
- JP2021513541A5 JP2021513541A5 JP2020542960A JP2020542960A JP2021513541A5 JP 2021513541 A5 JP2021513541 A5 JP 2021513541A5 JP 2020542960 A JP2020542960 A JP 2020542960A JP 2020542960 A JP2020542960 A JP 2020542960A JP 2021513541 A5 JP2021513541 A5 JP 2021513541A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- composition according
- pharmaceutical composition
- amino acid
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000162A JP2024038251A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体によるがんの処置方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630038P | 2018-02-13 | 2018-02-13 | |
| US62/630,038 | 2018-02-13 | ||
| US201862732828P | 2018-09-18 | 2018-09-18 | |
| US62/732,828 | 2018-09-18 | ||
| PCT/US2019/017177 WO2019160751A2 (en) | 2018-02-13 | 2019-02-08 | Methods for treating cancer with anti-pd-1 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000162A Division JP2024038251A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体によるがんの処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021513541A JP2021513541A (ja) | 2021-05-27 |
| JP2021513541A5 true JP2021513541A5 (https=) | 2022-02-16 |
| JPWO2019160751A5 JPWO2019160751A5 (https=) | 2022-02-16 |
Family
ID=67620026
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542960A Pending JP2021513541A (ja) | 2018-02-13 | 2019-02-08 | 抗ｐｄ−１抗体によるがんの処置方法 |
| JP2024000162A Pending JP2024038251A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体によるがんの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000162A Pending JP2024038251A (ja) | 2018-02-13 | 2024-01-04 | 抗ｐｄ－１抗体によるがんの処置方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12358984B2 (https=) |
| EP (1) | EP3752180A4 (https=) |
| JP (2) | JP2021513541A (https=) |
| KR (1) | KR20200119844A (https=) |
| CN (2) | CN111712255A (https=) |
| AU (2) | AU2019220495B2 (https=) |
| BR (1) | BR112020016331A8 (https=) |
| CA (1) | CA3090995A1 (https=) |
| CL (1) | CL2020002075A1 (https=) |
| IL (1) | IL276303A (https=) |
| MA (1) | MA52789A (https=) |
| MX (2) | MX2020008445A (https=) |
| SG (1) | SG11202007590TA (https=) |
| WO (1) | WO2019160751A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| MY204342A (en) | 2019-03-25 | 2024-08-24 | Alteogen Inc | Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection |
| EP4034163A4 (en) * | 2019-09-27 | 2023-11-08 | Merck Sharp & Dohme LLC | METHOD FOR TREATING METASTASIC TRIPLE NEGATIVE BREAST CANCER USING ANTI-PD-1 ANTIBODIES |
| ES3063234T3 (en) | 2019-12-20 | 2026-04-15 | Formycon Ag | Formulations of anti-pd1 antibodies |
| WO2021126906A1 (en) * | 2019-12-20 | 2021-06-24 | Merck Sharp & Dohme Corp. | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| CN112326961B (zh) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备 |
| CN112394102B (zh) * | 2020-11-05 | 2023-05-26 | 上海交通大学医学院附属瑞金医院 | 一种检测垂体功能减退症的标志物及其应用 |
| JP2024527517A (ja) | 2021-06-23 | 2024-07-25 | フォーマイコン アーゲー | 抗ｐｄ１抗体製剤 |
| US20250011453A1 (en) * | 2021-07-20 | 2025-01-09 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| CN113893343A (zh) * | 2021-10-16 | 2022-01-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗宫颈癌患者的药物中的用途 |
| US20250044295A1 (en) * | 2021-12-16 | 2025-02-06 | Merck Sharp & Dohme Llc | Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy |
| AU2023413756A1 (en) | 2022-12-21 | 2025-07-10 | Formycon Ag | Formulations of anti-pd1 antibodies |
| CN115925954A (zh) * | 2022-12-28 | 2023-04-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途 |
| WO2025140467A1 (zh) * | 2023-12-29 | 2025-07-03 | 上海复宏汉霖生物技术股份有限公司 | 稳定的高浓度抗pd-1抗体药物制剂 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP2002531466A (ja) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) * | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| ES2676205T3 (es) | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| EP2981821B2 (en) | 2013-04-02 | 2021-11-03 | Merck Sharp & Dohme Corp. | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| AU2014364606A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| CA2955612C (en) * | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| CA2955676A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| EP4098278A1 (en) * | 2014-11-13 | 2022-12-07 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| AR103726A1 (es) * | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
| US20160362489A1 (en) * | 2015-04-28 | 2016-12-15 | Bristol-Myers Squibb Company | Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody |
| US11078278B2 (en) | 2015-05-29 | 2021-08-03 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| CA3010617A1 (en) * | 2016-01-22 | 2017-07-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| JP6821693B2 (ja) | 2016-02-29 | 2021-01-27 | ジェネンテック， インコーポレイテッド | がんのための治療方法及び診断方法 |
| WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| EP3463453A1 (en) | 2016-05-23 | 2019-04-10 | Eli Lilly and Company | Combination of pembrolizumab and abemaciclib for the treatment of cancer |
| WO2017210624A1 (en) * | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treating a tumor |
| KR102561356B1 (ko) | 2016-09-14 | 2023-08-03 | 애브비 바이오테라퓨틱스 인크. | 항-pd-1 항체 및 이의 용도 |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| US11566073B2 (en) * | 2017-06-01 | 2023-01-31 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-PD-1 antibody |
-
2019
- 2019-02-08 MA MA052789A patent/MA52789A/fr unknown
- 2019-02-08 BR BR112020016331A patent/BR112020016331A8/pt unknown
- 2019-02-08 CA CA3090995A patent/CA3090995A1/en active Pending
- 2019-02-08 US US16/966,968 patent/US12358984B2/en active Active
- 2019-02-08 KR KR1020207026004A patent/KR20200119844A/ko not_active Ceased
- 2019-02-08 CN CN201980013286.8A patent/CN111712255A/zh active Pending
- 2019-02-08 CN CN202511206047.8A patent/CN120919306A/zh active Pending
- 2019-02-08 AU AU2019220495A patent/AU2019220495B2/en active Active
- 2019-02-08 WO PCT/US2019/017177 patent/WO2019160751A2/en not_active Ceased
- 2019-02-08 JP JP2020542960A patent/JP2021513541A/ja active Pending
- 2019-02-08 EP EP19754909.0A patent/EP3752180A4/en active Pending
- 2019-02-08 MX MX2020008445A patent/MX2020008445A/es unknown
- 2019-02-08 SG SG11202007590TA patent/SG11202007590TA/en unknown
-
2020
- 2020-07-26 IL IL276303A patent/IL276303A/en unknown
- 2020-08-10 CL CL2020002075A patent/CL2020002075A1/es unknown
- 2020-08-12 MX MX2024013016A patent/MX2024013016A/es unknown
-
2023
- 2023-09-01 US US18/459,842 patent/US20240026003A1/en not_active Abandoned
-
2024
- 2024-01-04 JP JP2024000162A patent/JP2024038251A/ja active Pending
-
2026
- 2026-02-12 AU AU2026201041A patent/AU2026201041A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513541A5 (https=) | ||
| JP2021513540A5 (https=) | ||
| JP2020522486A5 (https=) | ||
| JP2023027199A5 (https=) | ||
| JP2024102215A5 (https=) | ||
| JP2018518454A5 (https=) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2018503365A5 (https=) | ||
| JP2024102055A5 (https=) | ||
| RU2017117664A (ru) | Комбинация | |
| JP2020514310A5 (https=) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2021510697A5 (https=) | ||
| JPWO2019160751A5 (https=) | ||
| JP2025092589A5 (https=) | ||
| JP2021511372A5 (https=) | ||
| JP2021523170A5 (https=) | ||
| CN108079292A (zh) | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 | |
| JPWO2021154761A5 (https=) | ||
| JPWO2022270524A5 (https=) | ||
| JPWO2019160755A5 (https=) | ||
| JPWO2021123996A5 (https=) | ||
| IL307430A (en) | Methods for treating cancer with subcutaneous administration of ANTI-PD1 antibodies | |
| JPWO2019143607A5 (https=) |